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Abstract
The clinical phenotypes of human CoQ10-deficiency caused by COQ2 muta-
tions range from fatal neonatal disease to adult-onset multisystem atrophy. So
far, treatment options for these diseases are unsatisfactory. Here, we demon-
strate that supplementation of 4-hydroxybenzoic acid (4-HBA) fully restores
endogenous CoQ10-biosynthesis in COQ2-deficient cell lines. This was accom-
panied by increased protein expression of CoQ10-biosynthesis-enzymes as well
as a rescue of cell viability during stress conditions. In silico analysis suggested a
ligand transportation path for 4-HBA through the COQ2 protein towards the
mitochondrial matrix side. This process is apparently hindered by disease-caus-
ing mutations, which can be overcome by increasing 4-HBA concentrations.
Introduction
The mitochondrial respiratory chain requires several
cofactors for normal functioning.1 Among these cofactors,
coenzyme Q10 (CoQ10) features prominently. CoQ10 acts
as a lipid-soluble electron carrier from mitochondrial
complex I/II to complex III.2 In addition, CoQ10 partici-
pates in a number of aspects of cellular metabolism
including redox homeostasis and membrane stability.2,3
CoQ10 is mainly derived via endogenous biosynthesis,
depending on the interplay of at least 12 different
enzymes.4 One of these enzymes is COQ2 (4-HBA-poly-
prenyltransferase), which catalyzes the prenylation of 4-
hydroxybenzoic acid (4-HBA) with an all-trans polyprenyl
chain.5 Human COQ2-deficiency was first identified in
2006 in two siblings with infantile-onset nephropathy and
psychomotor regression.6 In the following, several other
patients were reported. The disease spectrum ranges from
neonatal-onset multisystem diseases to adult-onset ataxia
and cerebellar atrophy (Table S1).
Of note, clinical response to supplementation of CoQ10
was unsatisfactory in most COQ2-deficient patients
reported so far, which might be related to its poor oral
bioavailability (Table S1).7,8 Additional factors are that
CoQ10 is incorporated in all cell membranes (e.g., not specif-
ically mitochondrial) and its subcellular distribution
requires the action of the chaperone-like proteins COQ10A
and COQ10B.4 Therefore, it remains unclear if orally
administered CoQ10 effectively reaches the respiratory chain.
Methods
Cell culture
Fibroblasts cell lines were cultured in Dulbecco’s modified
Eagle’s medium (Life technologies) supplemented with
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10% fetal bovine serum (life technologies) and 1% peni-
cillin/streptomycin (life technologies) at 37°C in a humid-
ified atmosphere of 5% CO2. The use of patient-derived
cell lines was approved by the ethical committee of the
Medical Faculty, Heinrich-Heine-University D€usseldorf
(#5238). Biochemical details regarding the COQ2 and the
COQ9 cell lines were published previously (COQ2-def.1
and COQ9-def. see Danhauser et al., 2015; COQ2-def.2
and COQ2-def.3 see Jakobs et al., 2013; see also
Table S1).9,10
UPLC-ESI-MS/MS analysis
UPLC-ESI-MS/MS analysis was performed using an
Acquity UPLC-I Class (Waters, UK) coupled to a Waters
Xevo TQ-S tandem mass spectrometer (Waters, UK),
which was equipped with an ESI source operating in the
positive ion mode. Methodological details were described
previously.11
Compound supplementation studies
For compound testing, 400,000 cells/T75 flask were cul-
tured and medium was changed every third day contain-
ing one of the following substances: 4-hydroxybenzoic
acid (4-HBA), 4-hydroxyphenylpyruvic acid (4-HPPA), 4-
hydroxybenzaldehyde (4-HBAL), L-tyrosin and mevalonic
acid. Chemicals were purchased from Sigma-Aldrich. L-
tyrosin was dissolved in 1N NaOH. All other compounds
were dissolved in 0.03% DMSO (Sigma). After 14 days of
culturing, cells were harvested for UPLC-ESI-MS/MS
analysis.
Immunoblot analyses
Methodological details of immunoblot analyses were
described previously.11 The following primary antibodies
were used: COQ2 (anti-chicken; 1:1000; AS132713; Agris-
era), COQ4 (anti-rabbit; 1:500; 16654-1-AP; Proteintech),
COQ7 (anti-rabbit; 1:1000; 15083-1-AP; Proteintech) or
SDHA (anti-mouse; 1:1000; ab14715; Abcam).
Cell proliferation
Cell proliferation was determined using the crystal violet
assay as described previously.12
Live/dead assay
Cells viability was measured using Life/Dead assay
(Invitrogen) according to the manufactures protocol.
In silico analysis
The apo structure of the archaeal homolog of COQ2 from
Aeropyrum pernix was used as a template to build a
model of human COQ2 using the modeling server Phyre
2.13,14 The resulting model was manually inspected using
the program COOT.15 4-HBA binding sites were deter-
mined using the program AUTODOCK.16 After inspec-
tion of protein ligand interactions, putative binding sites
were visualized using the program Pymol (www.pymol.
org).
Results
Supplementation of 4-hydroxybenzoic acid
restores CoQ10 biosynthesis
4-hydroxybenzoic acid (4-HBA) is a small molecule,
which is derived from L-tyrosine (Fig. 1A). As depicted
in Figure 1B, 4-HBA as well as its precursor compounds
4-HPPA, 4-HBAL and, to a lesser extent, L-tyrosine res-
cued the biochemical defect in three COQ2-deficient
fibroblast lines. This phenomenon was dose-dependent
with significant effects of 4-HBA, 4-HPPA, and 4-HBAL
down to concentrations of 1 lmol/L (Fig. 1C). Of note,
treatment of fibroblasts with mevalonic acid (1000 lmol/
L for 2 weeks) had no effect on CoQ10 biosynthesis (not
shown).
4-hydroxybenzoic acid stimulates the
expression of CoQ10 biosynthesis enzymes
As depicted in Figure 2A and B, COQ2 protein levels
were normal in COQ2 patient cells compared to controls.
This phenomenon has been described before and indicates
that COQ2 patients express normal levels of a dysfunc-
tional COQ2 protein.17 4-HBA did not alter COQ2 levels
in control or patient fibroblasts. Regarding COQ4 and
COQ7, which are both crucial CoQ10 biosynthesis
enzymes, we observed reduced protein levels in the
COQ2-deficient patient fibroblasts. These abnormalities
significantly improved upon 4-HBA supplementation.
4-hydroxybenzoic acid rescues cell viability
of COQ2-deficient fibroblasts
We previously demonstrated that culturing of CoQ10-defi-
cent fibroblasts in galactose medium impairs cell viabil-
ity.11 In accordance, determination of cell proliferation
using the crystal violet assay showed severely impaired cell
growth of COQ2-deficient cells during galactose culture
stress conditions (Fig. 2C). Comparable findings were
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observed in fibroblasts with COQ9 deficiency. 4-HBA
treatment fully normalized cell proliferation in COQ2-
deficient cells but had no effects on COQ9-deficient
fibroblasts. In keeping with this observation, 4-HBA res-
cued cell viability in COQ2-deficient cells during galactose
culture (Fig. 2D).
In silico analysis of human COQ2
By applying homology modeling using the structure of
ApUbiA in its apo-state13 and subsequent ligand docking,
we obtained a model of human COQ2 in complex with
the 4-HBA ligand (Fig. 3A; sequence alignments see
Figure S2). We verified our docking results with the
structure, which was reported in the presence of the 4-
HBA ligand.13 The program AUTODOCK identified sev-
eral putative 4-HBA binding sites. One of these binding
sites corresponded well with the binding site in the ApU-
biA crystal structure.13 The crystalized ligands are shown
in cyan, whereas the docked ligand is highlighted in white
(Fig. 3A; left panel, magnified region). The amino acids
interacting with the ligand as observed in the crystal
structure are completely conserved in human COQ2
(highlighted in cyan, Fig. 3B, left panel and Fig. S1, right
panel). Of note, Cheng & Li (2014) demonstrated for the
ApUbiA protein that mutations of these interacting
Figure 1. 4-hydroxybenzoic acid (4-HBA) metabolic pathway and effects of 4-HBA on CoQ10 biosynthesis in human COQ2 deficiency. (A)
Schematic illustration of the 4-hydroxybenzoic acid (4-HBA) metabolic pathway in human cells. (B) Quantitative analysis of CoQ10 levels in control
and COQ2 deficient fibroblast cell lines measured by UPLC-MS/MS. For details regarding the cell lines COQ2-def.1, COQ2-def.2 and COQ2-def.3
see Table S1. The different cell lines were treated with 4-hydroxybenzoic acid (4-HBA), 4-hydroxyphenylpyruvic acid (4-HPPA), 4-
hydroxybenzaldehyde (4-HBAL), and L-tyrosin (L-Tyr), respectively. The effect of each concentration was expressed relative to values obtained with
vehicle-treated control cells, which was set at 100%, measured on the same day. (C) Quantitative analysis of CoQ10 levels in control and COQ2-
def.1 fibroblast using different concentrations of 4-HBA, 4-HPPA, 4-HBAL and L-Tyr. Statistics: ***P < 0.001) and **P < 0.01) relative to the
indicated condition. Statistical significance was assessed using Student’s t-test. All experimental data was obtained in at least three independent
experiments.
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residues result in an almost complete loss of activity, indi-
cating that this is the main catalytic site.13 Interestingly,
we further obtained several additional putative 4-HBA
binding sites (Fig. 3A). It appears that these binding sites
are located along a tunnel-like structure (Fig. 3A, right
panel). We then mapped the clinically-described mutants
of COQ2 onto our model. As shown in Figure 3B, the
majority of these mutants are located near the putative
tunnel where 4-HBA passes through the protein.
Discussion
Clinical response to CoQ10 substitution in CoQ10 defi-
ciency disorders varies greatly among the different
underlying genetic defects. As discussed above, especially
in the severe forms, results of CoQ10 treatment are unsat-
isfactory. Therefore, the idea of metabolic bypass treat-
ment using CoQ precursor compounds emerged.11,18
Here, we identified 4-HBA supplementation as an
effective treatment for COQ2-deficient fibroblasts. 4-HBA
is a water-soluble small molecule, which is derived from
L-tyrosine (Fig. 1A). The finding that 4-HBA rescues
COQ2 deficiency initially appeared to be surprising since
the concept of metabolic bypass strategies mainly implies
that a substrate is provided, which enters the metabolic
pathway distal of the enzymatic block.11 In contrast, 4-
HBA is a direct substrate of COQ2, which mediates its
condensation with the polyisoprenoid side chain. This
Figure 2. 4-HBA stimulates the expression of CoQ10 biosynthesis enzymes and rescues cell viability in COQ2-deficient fibroblasts. (A)
Representative immunoblot analysis in control as well as two COQ2-deficient fibroblast cell lines. Protein levels of COQ4 and COQ7 are reduced
in cell lines with COQ2 deficiency. Supplementation of 4-hydroxybenzoic acid (4-HBA) rescued this abnormality. Complex II (SDHA) was used as
loading control. Results shown are representative for three independent experiments. (B) Quantitative data of immunoblot analyses confirming the
results depicted in A). (C) Quantitative analysis of cell proliferation using the crystal violet assay. Results were expressed relative to values obtained
with the vehicle-treated condition cultured in glucose medium, which was set at 100% for each individual condition (dotted line). A COQ9-
deficient fibroblast cell line was used as an additional control. Results indicate a severe growth defect of all CoQ10-deficient cell lines in galactose
medium, which was specifically rescued by 4-HBA treatment in COQ2-deficient cell lines. (D) Live/Dead assay with similar conditions as depicted
in C). Also in this assay, 4-HBA specifically rescued cell viability of galactose-cultured COQ2 cells. Statistics: ***P < 0.001 and **P < 0.01 relative
to the indicated condition. Statistical significance was assessed using Student’s t-test. All experimental data was obtained in at least three
independent experiments.
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suggests that clinically-relevant COQ2 mutations are asso-
ciated with a residual enzyme activity that can be stimu-
lated by increasing substrate availability. Interestingly, as
shown in Figure 2A, COQ2 protein levels in several
patient-derived fibroblast lines were not reduced. This
indicates that mutant COQ2 is still active but operates at
a slow rate.
Another surprising finding of our study was the full
restoration of CoQ10 levels in COQ2 patient fibroblasts
with 4-HBA treatment. Metabolic bypass strategies that
we performed previously in the context of COQ7 and
COQ9 deficiency yielded only moderate effects on CoQ10
biosynthesis.11 This treatment response reminded us of
defects involving cofactor transport processes (e.g., thi-
amin or riboflavin metabolism disorders), which can be
compensated by high-dose supplementation of the sub-
strate. Interestingly, COQ2 is a transmembrane protein of
the inner mitochondrial membrane that is in contact with
the mitochondrial intermembrane space as well as the
mitochondrial matrix.19 However, no transport functions
have been described for COQ2 so far. Importantly, in our
experiments 4-HBA seemed to be the rate-limiting
Figure 3. In silico analysis with homology modeling and ligand docking of the human COQ2 protein. (A) Structural model of human COQ2
based on the ApUbiA crystal structure (PDB entry: 4OD5). Left panel: cartoon representation with the 4-HBA ligand bound. The binding site of 4-
HBA as identified in the ApUbiA crystal structure is highlighted in cyan. The magnified region demonstrates the co-localization of the binding site
in the crystal structure with one of the binding sites identified in this study. In addition, ligand docking revealed several additional putative
binding sites, which are colored differently. Right panel: surface representation of the human COQ2 model. The identified ligand binding sites are
shown in sticks. Ligand docking appears to follow a tunnel-like structure, which directs 4-HBA to the final activity site for conversion (the ligand
transportation path is highlighted by an arrow). (B) Known mutations are docked onto the human COQ2 model. Left panel: the mutants
published by Cheng & Li (2014) in ApUbiA, which almost completely abolish the enzymatic activity are shown in cyan.13 The patient mutations as
described in Table S1 are shown as stick representation. Severity of the mutations in the clinical context is highlighted as follows: severe
(Trp254Arg Ala302Val Ser146Asn and Arg387Xp) in red, intermediate (Gly390Ala Tyr297Cys and Arg197His) in blue and late-onset (Met128Val
and Val393Ala) in magenta. The mutations that were investigated in this study are indicated by dotted lines. Right panel: surface representation
of the COQ2 model with the possible 4-HBA binding sites. The mutations are color-coded as described above. Please note that the mutations
described so far are mainly clustering around the proposed tunnel-like structure.
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compound since stimulation of the isoprenoid pathway
using mevalonic acid was ineffective.
Of note, although COQ2 was already described by
Winrow et al. in 1969, its exact function is still not fully
understood.20 In order to gain more insights into 4-HBA
metabolism via COQ2 we performed in silico analysis
with homology modeling and ligand docking. As shown
in Figure 3, our analysis revealed several interesting
aspects: First of all, the putative catalytic site of COQ2,
which binds 4-HBA and mediates the condensation with
the polyprenyl side chain is highly conserved. No patient-
related mutations directly affecting these residues were
described so far suggesting that such defects may be
incompatible with life. Moreover, we identified several
additional putative 4-HBA binding sites appearing to be
located along a tunnel-like structure (Fig. 3A). It is
tempting to speculate that this structure constitutes a
ligand transportation path for 4-HBA through the COQ2
protein. This idea is further supported by the observation
that clinically-relevant COQ2 mutations cluster around
this tunnel-like structure, indicating that they hinder 4-
HBA transport. We suggest that increasing 4-HBA con-
centrations might accelerate substrate flow through the
COQ2 protein thereby reactivating CoQ10 biosynthesis.
This reactivation is actually highlighted by our immuno-
blot analyses that revealed a drastic increase in CoQ10
biosynthesis protein expression levels in COQ2-deficient
cell lines upon 4-HBA treatment.
In view of the above findings, further in vivo studies
will be of major importance to establish a drug profile
analysis for 4-HBA and to evaluate its therapeutic poten-
tial under clinical conditions. Moreover, testing 4-HBA in
the context of different clinically relevant mutations will
be helpful to investigate differences in drug response
based on the underlying genetic defect.
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Supporting Information
Additional Supporting Information may be found online
in the supporting information tab for this article:
Figure S1. It depicts a cartoon representation of the crys-
tal structure of ApUbiA in the substrate bound state. The
essential residues are shown, which most likely constitute
the main catalytic site of the enzyme.
Figure S2. It depicts a sequence alignment of the ApUbiA
protein with the human COQ2 sequence.
Table S1. It provides an overview of individuals with
COQ2 defects published in the literature. The table illus-
trates the different clinical phenotypes associated with
COQ2 deficiency and indicates the poor response of this
disorder to oral CoQ10 supplementation.
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